Before introducing genomic epidermal growth factor receptor (EGFR) inhibitor therapy, despite platinum-based combination chemotherapy, the overall survival (OS) of most patients with advanced non-small-cell lung cancer (NSCLC) is less than one year [2]. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.